10-Q: Clene Reports Q2 2025 Loss, Pursues ALS Approval

Clene Inc. reported a reduced net loss in Q2 2025, while continuing to advance its lead drug candidate CNM-Au8 for ALS and MS, despite ongoing liquidity concerns and internal control weaknesses.

Summary

• Clene Inc. reported a net loss of $7.4 million for the three months ended June 30, 2025, an improvement from $6.8 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $8.2 million, significantly lower than $17.9 million for the six months ended June 30, 2024.
• Total revenue for the six months ended June 30, 2025, decreased by 34% to $108 thousand from $164 thousand in the prior year period.
• Research and development expenses decreased by 50% to $5.0 million for the six months ended June 30, 2025, compared to $10.0 million in the prior year.
• General and administrative expenses decreased by 25% to $5.0 million for the six months ended June 30, 2025, from $6.7 million in the prior year.
• Cash and cash equivalents stood at $7.3 million as of June 30, 2025, down from $12.2 million at December 31, 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, was $9.8 million, an improvement from $13.4 million in the prior year period.
• The company has an accumulated deficit of $290.3 million as of June 30, 2025.
• Subsequent to June 30, 2025, the company raised $1.9 million from equity sales and $1.5 million from new senior secured convertible promissory notes.
• The maturity date for the 2024 Senior Secured Convertible Promissory Notes was extended to February 13, 2027, and monthly principal repayments were deferred to September 2026.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit 'going concern' warning, significant cash burn, and identified material weaknesses in internal controls. While there are positive developments in clinical trials and recent capital raises, these are overshadowed by the fundamental financial instability and the inherent uncertainties of drug development and regulatory approval. The delays in debt repayment, while providing short-term relief, also highlight the financial strain.

Positives

• Net loss significantly decreased by 54% for the six months ended June 30, 2025, to $8.2 million from $17.9 million in the prior year.
• Loss from operations decreased by 40% for the six months ended June 30, 2025, to $9.9 million from $16.6 million in the prior year.
• Net cash used in operating activities improved, decreasing to $9.8 million for the six months ended June 30, 2025, from $13.4 million in the prior year.
• Received written guidance from the FDA in December 2024 regarding a potential accelerated approval pathway for CNM-Au8 in ALS.
• FDA provided constructive feedback on the statistical analysis plan for EAP NfL biomarker analyses in Q2 2025.
• Two competing ALS treatments (ABBV-CLS-7262 and DNL343) failed to meet primary and key secondary endpoints in early 2025, potentially reducing competition.
• Successfully raised $1.9 million from equity sales and $1.5 million from new senior secured convertible promissory notes subsequent to the reporting period.
• Maturity date of 2024 SSCP Notes extended to February 13, 2027, and principal repayments deferred to September 2026, providing financial flexibility.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern beyond one year without additional financing.
• Cash and cash equivalents decreased to $7.3 million as of June 30, 2025, from $12.2 million at December 31, 2024.
• Total revenue decreased by 34% for the six months ended June 30, 2025, to $108 thousand.
• The company has an accumulated deficit of $290.3 million as of June 30, 2025, and has never been profitable.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2024 and 2023, indicating deficiencies in control environment, reconciliations, segregation of duties, and IT general controls.
• FDA noted that whether NfL can serve as a reasonably likely surrogate endpoint for CNM-Au8 in ALS and whether the magnitude of change observed is reasonably likely to predict clinical benefit would be a matter of review, indicating continued uncertainty.

Risks

• Ability to obtain additional financing to sustain current operations and meet obligations.
• Uncertainty of regulatory approval and market acceptance for product candidates.
• Reliance on third-party contract research organizations (CROs) and manufacturers.
• Challenges in protecting intellectual property.
• Potential for litigation or claims based on intellectual property, patent, product, or regulatory factors.
• Ability to attract and retain necessary employees to support growth.
• Requirement to maintain unrestricted cash and cash equivalents of at least $2.0 million to avoid acceleration of 2024 SSCP Notes.
• SSCPN Default Feature: potential penalty of 10% of outstanding principal and accrued interest if certain events of default occur.
• SSCPN Collateral Deficiency Fee: additional 10% per annum interest if collateral proceeds are insufficient to satisfy obligations.
• SSCPN Registration Fee: potential penalty of 2% of face value of 2024 SSCP Notes upon initial failure to register shares, up to 10% maximum, for continued failure.
• Contingent repayment obligations to National Multiple Sclerosis Society (NMSS) grants (2019 Grant: $0.2 million to $1.5 million; 2023 Grant: $0.3 million to $3.0 million) upon future commercial sales or specific monetization events.

Future Outlook

The company expects to incur additional losses in the future as it advances clinical-stage drug candidates, continues preclinical research, and initiates new clinical trials. Significant revenues are not anticipated until successful development and regulatory approval of a drug candidate. The company plans to submit an NDA for CNM-Au8 in ALS by the end of 2025 under an accelerated approval pathway, contingent on NfL data concordance from ongoing EAPs. A confirmatory Phase 3 trial, RESTORE-ALS, is planned for the first half of 2026, contingent on funding. An end of Phase 2 meeting with the FDA is confirmed for Q3 2025 to discuss a planned Phase 3 study for CNM-Au8 in MS focusing on cognition improvement.

Management Comments

• We expect that within the next twelve months, we will not have sufficient cash and other resources on hand to sustain our current operations or meet our obligations as they become due unless we obtain additional financing.
• We have implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts, reducing employee compensation, and elimination of certain staff positions.
• We have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued.
• We intend to follow the FDA’s recommendation to provide data from the ongoing EAPs and believe we can address the FDA’s requests.
• We plan to submit an NDA by the end of 2025 under an accelerated approval pathway, assuming the NfL data from our ongoing EAP funded by a National Institutes of Health grant (the ACT-EAP) is concordant with NfL results shown in the HEALEY ALS Platform Trial.
• We also plan to commence a confirmatory Phase 3 trial, RESTORE-ALS, in the first half of 2026, contingent on funding.
• We plan to work closely with regulatory health authorities from the FDA, European Medicines Agency and other international regulatory bodies, MS experts, and patient representatives to determine the proper path to advance CNM-Au8 into Phase 3 and potential future approval.

Industry Context

Clene Inc. operates in the highly competitive and capital-intensive clinical-stage pharmaceutical industry, specifically targeting neurodegenerative diseases like ALS, MS, and Parkinson's Disease. The recent failures of competing ALS treatments (ABBV-CLS-7262 and DNL343) in the HEALEY ALS Platform Trial highlight the significant challenges and high unmet medical needs in this therapeutic area. Clene's focus on clean-surfaced nanotechnology (CSN) therapeutics represents a novel approach, but the path to regulatory approval is long and uncertain, as evidenced by the ongoing discussions with the FDA regarding surrogate endpoints and the need for confirmatory trials. The industry is characterized by high R&D costs, long development cycles, and significant reliance on external funding and regulatory milestones.

Comparison to Industry Standards

• The company's significant accumulated deficit of $290.3 million and ongoing net losses are common for clinical-stage biotechnology companies that have not yet brought a product to market.
• The reliance on equity and debt financing, including ATM facilities and convertible notes, is a standard practice for pre-revenue biopharmaceutical firms to fund extensive R&D and clinical trials.
• The high R&D expenses, even with a 50% reduction in the current period, are typical for companies with multiple drug candidates in clinical development, especially for complex neurological disorders.
• The challenges in obtaining FDA accelerated approval, as seen with the need for additional NfL data and further meetings, are consistent with the rigorous regulatory environment for novel therapies, particularly for severe conditions like ALS where surrogate endpoints are closely scrutinized.
• The failure of competitor treatments (ABBV-CLS-7262 from Calico Life Sciences LLC and AbbVie Inc., and DNL343 from Denali Therapeutics Inc.) in the HEALEY ALS Platform Trial underscores the difficulty of developing effective treatments for ALS, positioning Clene's progress, albeit slow, as potentially significant if successful.

Corporate Governance

Related Party Transactions

• Product and royalty revenue generated from 4Life Research LLC, an international supplier of health supplements, stockholder, and related party, under exclusive supply and license agreements.
• The 2024 Senior Secured Convertible Promissory Notes (totaling $10.0 million) were sold to related parties, including an entity controlled by a board member, 4Life, and an entity controlled by the chairman of 4Life (who is also a board member of a Clene subsidiary).

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing equity financing and potential conversion of convertible notes and warrants. The 'going concern' warning indicates substantial risk to investment value. Positive clinical trial progress could lead to upside, but regulatory hurdles and funding needs remain high.
• **Employees:** Subject to cost-saving initiatives, including reduced compensation and staff elimination, which could impact morale and retention. Future hiring and expansion are contingent on funding and regulatory success.
• **Customers (4Life Research LLC):** Continue to be a primary source of limited product and royalty revenue, indicating an ongoing business relationship for dietary supplements.
• **Creditors (Holders of SSCP Notes, DHCD, Advance Cecil Inc., Avenue):** The company's ability to meet debt obligations is uncertain without additional financing. The recent amendment to the 2024 SSCP Notes defers principal payments, providing short-term relief but extending the repayment period. The collateralization of the 2024 SSCP Notes provides some security for those specific creditors.
• **Regulatory Bodies (FDA, EMA):** The company is actively engaged with the FDA regarding accelerated approval pathways for CNM-Au8, indicating ongoing regulatory scrutiny and collaboration.

Next Steps

• Complete additional NfL biomarker collection and analyses to support NDA submission for CNM-Au8 in ALS in Q4 2025.
• Attend an additional Type C meeting with the FDA in Q3 2025 to review long-term survival benefit data for CNM-Au8 in ALS.
• Submit an NDA for CNM-Au8 in ALS by the end of 2025 under an accelerated approval pathway, contingent on NfL data concordance.
• Commence a confirmatory Phase 3 trial, RESTORE-ALS, in the first half of 2026, contingent on funding.
• Expect topline results for the second dosing cohort of REPAIR-MS (Phase 2) in Q3 2025.
• Attend an end of Phase 2 meeting with the FDA in Q3 2025 to review VISIONARY-MS trial results and discuss a planned Phase 3 study for CNM-Au8 in MS.
• Continue to implement cost-saving initiatives, including delaying and reducing certain R&D programs and commercialization efforts, reducing employee compensation, and eliminating staff positions.
• Continue remediation activities for identified material weaknesses in internal control over financial reporting, including adding technical accounting resources and enhancing corporate oversight.

Key Dates

Recommendation

The 'going concern' warning is the most critical factor, indicating a high probability of financial distress or further dilutive capital raises. While the company has reduced its net loss and is making progress in clinical trials, its cash position is declining, and it remains heavily reliant on external financing. The identified material weaknesses in internal controls add another layer of risk regarding financial reporting reliability. The recent capital raises and debt deferrals provide temporary relief but do not fundamentally resolve the underlying liquidity issues. Given the significant financial risks and uncertainties surrounding regulatory approvals and future funding, a seasoned investor would likely consider selling to avoid potential further capital erosion or significant dilution.

Keywords

Biotechnology, Pharmaceutical, Neurodegenerative diseases, ALS, Multiple Sclerosis, Parkinson's Disease, CNM-Au8, Clinical trials, FDA approval, Nanomedicine, SEC filing, 10-Q, Going concern, Capital raise, Warrants, Convertible notes